M
M. Cravets
Researcher at Biogen Idec
Publications - 15
Citations - 2362
M. Cravets is an academic researcher from Biogen Idec. The author has contributed to research in topics: Rituximab & Rheumatoid arthritis. The author has an hindex of 7, co-authored 10 publications receiving 2270 citations.
Papers
More filters
Journal ArticleDOI
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward C. Keystone,J.E. Loveless,Gerd-Rüdiger Burmester,M. Cravets,E. W. Hessey,T. Shaw,Mark C. Totoritis +12 more
TL;DR: At 24 weeks, a single course of rituximab with concomitant MTX therapy provided significant and clinically meaningful improvements in disease activity in patients with active, longstanding RA who had an inadequate response to 1 or more anti-TNF therapies.
Journal ArticleDOI
Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis An Open-Label Extension Analysis
Edward C. Keystone,Roy Fleischmann,Paul Emery,Daniel E. Furst,Ronald F van Vollenhoven,Joan M. Bathon,Maxime Dougados,Andrew R. Baldassare,Gianfranco Ferraccioli,Andrew Chubick,James Udell,M. Cravets,Sunil Agarwal,Simon Cooper,Fabio Magrini +14 more
TL;DR: Findings indicate that patients treated with repeated courses of rituximab have sustained clinical responses with no new adverse events.
Journal ArticleDOI
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
Edward C. Keystone,Paul Emery,Charles Peterfy,Paul P. Tak,Stanley Cohen,Mark C. Genovese,Maxime Dougados,Gerd R Burmester,Maria Greenwald,Tore K Kvien,Sarah Williams,David Hagerty,M. Cravets,T. Shaw +13 more
TL;DR: This study provides the first evidence that a B cell-targeted therapy-rituximab-can significantly inhibit the progression of structural joint damage in patients with RA with long-standing, active and treatment-resistant disease.
Journal ArticleDOI
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.
E.C. Keystone,G.-R. Burmester,Richard Furie,J.E. Loveless,Paul Emery,Joel M. Kremer,Paul P. Tak,Michael S. Broder,E. Yu,M. Cravets,F. Magrini,F. Jost +11 more
TL;DR: Rituximab produced rapid, clinically meaningful, and statistically significant improvements in patient-reported pain, fatigue, functional disability, health-related quality of life, and disease activity.
Journal ArticleDOI
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
TL;DR: Lesinurad achieves clinically relevant and statistically significant reductions in sUA in combination with allopurinol in patients who warrant additional therapy on allopURinol alone.